New Study Finds Postoperative Respiratory Depression Associated with Increased Hospital Charges

A poster of this study will be displayed at the International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting on Tuesday, May 23 from 8 am to 2 pm.

SAN DIEGO – May 23, 2017 – An abstract and poster presented by CogenDx, which offers genetic testing to identify how a patients’ genetic profile may impact his or her response to certain medications, details the results from a recent study into the occurrence of postoperative respiratory depression after inpatient surgery. The study of 17,727 patients found that 4 percent of patients undergoing inpatient surgery experienced postoperative respiratory depression, and the average hospital charges for these patients were $9,180 higher than similar patients who did not experience such respiratory depression.

Read More →

Treatment of Postoperative Pain with Multiple Opioids is Associated with Increased Hospital Charges

The abstract and poster will be displayed at the International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting on Tuesday, May 23.

SAN DIEGO – May 22, 2017 – A new study examined the occurrence of patients undergoing treatment with multiple opioids for postoperative pain following inpatient surgery, and calculates the associated hospital charges. The findings reveal that of 17,727 patients, 33 percent were treated with three or more different injectable opioids on the day of surgery. The average hospital charges for these patients were $2,559 higher compared to similar patients who weren’t treated for pain in a similar manner. The study was conducted by CogenDx, which offers genetic testing to identify how a patients’ genetic profile may impact his or her response to certain medications.

Read More →

Discovery of Novel Screening Test That Can Identify Patients at Risk of Life-Threatening Side Effect with Certain Anticonvulsant Medications

CogenDx will present the study at the Annual Clinical Genetics Meeting of the American College of Medical Genetics on March 23, 2017

SAN DIEGO – March 23, 2017 – A new genetic test has been discovered that allows for fast and accurate identification of individuals who carry HLA-B*15:02 and who are therefore at risk for a rare yet potentially deadly side effect of certain medications used to treat seizures and bipolar disorder. The gene HLA-B*15:02 is strongly associated with life-threatening severe skin hypersensitivity reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis in patients treated with carbamazepine and related medications such as lamotrigine and phenytoin.

Read More →

New Study Reveals Americans Have Substantial Differences in Drug-Metabolizing Gene

CogenDx will present the study at the American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Washington D.C., March 15-18

SAN DIEGO – March 16, 2017 – CogenDx, which offers genetic testing to identify how a patients’ genetic profile may impact his or her response to certain medications, unveils one of the largest studies of variation of the drug-metabolizing gene CYP2D6 in the US population. The study revealed that a wide range of different CYP2D6 genes, including the difficult-to-detect structural variants, are found in Americans. CYP2D6 metabolizes approximately one-quarter of prescribed medications, and the observed genetic diversity may explain why many patients do not respond well or have intolerable side effects when taking medications such as certain antidepressants, antipsychotics and opioids. The study was a collaboration with Children’s Mercy Kansas City.

Read More →